To address these knowledge gaps, we investigated the antitumor effects of squamocin in preclinical models and clinical samples from HNSCC, GC, and CRC, where both EZH2 and MYC activation converge. The gene discussed is EZH2; the disease is head and neck squamous cell carcinoma.